Synthetic Polymeric Scaffolds for PRP Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering platelet-rich plasma (PRP) and other blood extracts face limitations such as inconsistent mechanical and biological properties of scaffolds, difficult processing techniques, requirement for specialized equipment and personnel, growth factor release not responsive to tissue regeneration needs, and poor control over polymerization and degradation processes, leading to inefficient healing support.
Innovation Solution
Development of a composition comprising a biomaterial, such as a fully synthetic polymeric biomaterial, mixed with blood extracts, which can be rapidly polymerized in situ to form a scaffold that conforms to the defect site, degrades as new tissue is formed, and releases growth factors in response to tissue regeneration, using monomers like PEG-norbornene and enzymatically degradable peptides for controlled polymerization and degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional PRP preparation methods are used, then platelet concentration is achieved, but mechanical and biological properties of scaffolds are inconsistent
Solution Approach 1:
The patent changes the fundamental parameters of PRP preparation by using a standardized centrifugation protocol with specific speed and time parameters, and by controlling the final product to have consistent platelet concentration ranges. This transforms variable traditional preparation into a reproducible process with defined parameters, ensuring consistent mechanical and biological properties across different batches and preparations.
2Productivity
If PRP is activated with thrombin and calcium chloride, then growth factors are released and clotting occurs, but handling properties and control over polymerization are poor
Solution Approach 1:
The patent applies preliminary action by pre-activating platelets with thrombin and calcium chloride during the centrifugation process itself, rather than activating them at the time of application. This preliminary activation allows growth factors to be released and incorporated into the forming scaffold structure during preparation, while the scaffold maintains workable handling properties until implantation when final clotting occurs.
Solution Approach 2:
The patent creates a dynamic system where the scaffold transitions from a liquid slurry state during preparation and implantation to a solid clotting state after deployment. By controlling the timing and location of final clotting, the system maintains ease of operation during delivery while ensuring effective growth factor release and scaffold formation at the target site.
3Ease of operation
If PRP is injected directly into tissues, then spontaneous activation occurs upon contact with extracellular matrix, but control over activation timing and location is limited
Solution Approach 1:
The patent performs preliminary platelet activation during the centrifugation process, so that platelets are primed and ready for controlled clotting upon scaffold formation at the defect site. This preliminary action provides better control over activation timing compared to direct injection, while maintaining the simplicity of minimally invasive delivery through the scaffold implantation approach.
4Adaptability or versatility
If broad variability in PRP production is accepted, then different concentrating techniques can be used, but therapeutic consistency is compromised
Solution Approach 1:
The patent establishes specific parameter ranges for platelet concentration, hematocrit, and volume that define the therapeutic window for effective PRP scaffolds. By specifying these critical parameters, the patent enables different concentrating techniques to be used adaptively while ensuring that all preparations meet the same therapeutic consistency standards, reconciling flexibility with reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a consistent, reproducible scaffold that maintains growth factors at the site of action, degrades in sync with tissue formation, and produces well-defined degradation products, enhancing the effectiveness of PRP delivery and tissue regeneration by improving handling properties and release kinetics.
Implementation Method 1
PRP and other blood extracts also contain other proteins, such as collagen, fibrinogens and fibronectin, amongst others, that have both signaling and scaffolding properties. Upon delivery of PRP to a tissue or bone defect, these proteins can form a gel that serves as a provisional matrix (e.g., a scaffold) that can support tissue or bone regeneration.
Implementation Method 2
The platelets collected in PRP can be activated by the addition of thrombin and calcium chloride, which induces the release of these factors from alpha granules.
Implementation Method 3
Development of a composition comprising a biomaterial, such as a fully synthetic polymeric biomaterial, mixed with blood extracts, which can be rapidly polymerized in situ to form a scaffold that conforms to the defect site, degrades as new tissue is formed
Data Source
AI summary
The disclosure provides biomaterials including scaffolds that include blood products including blood fractions and products including platelets for administration to subjects in need thereof. More specifically, the scaffolds based on step growth polymers are enriched with blood extracts that contain platelet rich plasma (PRP) and/or extracts of platelets. Compositions comprising a biomaterial or precursor thereof and a blood extract are provided, as are methods of making and using the biopolymers or precursors thereof. Kits and articles of manufacture comprising the biopolymers or precursors thereof are also described.